MelaFind -- a device that creates digital images of suspicious skin growths and compares them to a database of thousands of scans to analyze for signs of melanoma skin cancer -- has been approved by the U.S. Food and Drug Administration.
The non-invasive diagnostic can help doctors decide whether to biopsy skin growths in their early stages, when skin cancer is nearly 100 percent curable, device maker Mela Sciences said in a news release.
While the new technology can recommend to doctors whether to perform a biopsy, it is not intended to confirm a clinical diagnosis of melanoma, Mela said.
The company is based in Irvington, N.Y.
Copyright © 2011 HealthDay. All rights reserved.
For more on melanoma, search articles in the Cosmetic Dermatology archives using our Topic Collections.